tiprankstipranks
Tiziana Secures NIH Grant for Alzheimer’s Research
Company Announcements

Tiziana Secures NIH Grant for Alzheimer’s Research

Tiziana Life Sciences (TLSA) has released an update.

Pick the best stocks and maximize your portfolio:

Tiziana Life Sciences has been awarded a $4 million NIH grant to fund research on its pioneering intranasal anti-CD3 monoclonal antibody foralumab as a potential treatment for Alzheimer’s disease. The grant will accelerate the company’s research efforts, including preclinical studies and preparations for clinical trials targeting immune system modulation to slow the disease’s progression. Tiziana is advancing its development pipeline with this support, highlighting its commitment to addressing the urgent need for new therapeutic options in neurodegenerative diseases.

For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTiziana Life Sciences Advances Alzheimer’s Treatment with Intranasal Foralumab
TheFlyTiziana Life Sciences announces first patient dosed with intranasal foralumab
TipRanks Auto-Generated NewsdeskTiziana Life Sciences Expands MS Clinical Trial Network
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App